(C) Reuters. FILE PHOTO: A vial and syringe are seen in front of a displayed Pfizer logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration
(Reuters) -Pfizer Inc said on Monday it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech.
The early-stage trial, conducted in the United States, will test the vaccine in healthy adults ages 65- 85.
“The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA. Influenza remains an area where we see a need for vaccines,” said Kathrin Jansen, head of vaccine research and development at Pfizer (NYSE:PFE).
The study will test the safety and immune responses of the vaccine, compared to another FDA-approved influenza vaccine.
Pfizer begins study of mRNA flu vaccine
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.